SNAI1 and familial pancreatic carcinoma: Moreover, miR-30a also appeared to enhance gemcitabine response in vivo (Fig. 5e, g–i), thereby implicating miR-30a-SNAI1 axis as potential treatment option for pancreatic cancers.